C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61P 17/06 (2006.01) A61P 35/00 (2006.01) C12N 5/18 (2006.01) C12N 15/13 (2006.01) G01N 33/577 (2006.01)
Patent
CA 2575348
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF- IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or anti-VEGF antibodies and/or antibodies directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
La présente invention concerne de nouveaux anticorps pouvant se fixer de manière spécifique au récepteur du facteur de croissance I semblable à l'insuline IGF-IR et/ou pouvant inhiber de manière spécifique l'activité tyrosine kinase dudit IGF-IR, en particulier des anticorps monoclonaux murins, chimériques et humanisés, ainsi que des séquences d'acides aminés et d'acides nucléiques codant pour lesdits anticorps. L'invention concerne également l'utilisation de ces anticorps comme médicaments destinés au traitement prophylactique et/ou thérapeutique des cancers surexprimant l'IGF-IR, ou toute autre pathologie associée à la surexpression dudit récepteur, ainsi que dans des méthodes ou des kits de diagnostic de maladies associées à la surexpression de l'IGF-IR. L'invention concerne enfin des produits et/ou des compositions contenant lesdits anticorps en combinaison avec des anticorps anti-EGFR, et/ou des anticorps anti-VEGF, et/ou des anticorps dirigés contre d'autres facteurs de croissance associés à la progression tumorale ou à la métastase, et/ou des composés et/ou des agents anticancéreux ou des agents conjugués à des toxines, et leur utilisation dans la prévention et/ou le traitement de certains cancers.
Corvaia Nathalie
Goetsch Liliane
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Pierre Fabre Medicament
LandOfFree
Novel anti-igf-ir antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel anti-igf-ir antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel anti-igf-ir antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1928901